Clinical Trial Update: Scleroderma Treatment With Celution Processed ADRCs Registry

View source ↗

Summary

A clinical trial evaluating Celution-processed adipose-derived regenerative cells (ADRCs) for systemic sclerosis has been withdrawn from the registry.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Celution Processed ADRCs (adipose-derived regenerative cells (ADRCs))

Snippet

Sponsor: Cytori Therapeutics | Conditions: Scleroderma | Status: WITHDRAWN